4finance schreef op 6 juni 2019 21:33:
Zo maar wat posts van het USA forum vandaag... Ik hoop een behoorlijke positie in die hut. Geen idee van er aan de han is. Maar deze constante daling is wel opmerkelijk.
Well, we've all seen days like this in small biotech. Stock slides for no good reason. They have plenty of cash a great partnership and AFM13 works. No question. So why the dip? Bad data? I doubt it.
I don't see a good reason to sell.
I think some investors were pushed to sell because recent developments with MGNX. But even though the target of MGNX antibody is the same, the affinities are far different and that's why AFM13 will deliver as it delivered in earlier trials.
$200 mln Market Cap
$130 mln in cash
AMF13 proven to work with 88% ORR, full data read out June 18-22
Registration clinical trial about to start, This could be fast track from FDA we should here in coming days.
$5 bln in milestones from Genentech, First milestone received, more likely more to come
Edge technology ROCK platform with more to come